Second-generation antipsychotics did not improve outcomes and increased costs for patients with Alzheimer disease and psychosis

Seitz, Dallas P.; Gruneir, Andrea; Rochon, Paula A.
March 2008
ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p27
Academic Journal
The article focuses on the randomized placebo-controlled trial investigating if second-generation antipsychotics improves health and reduces costs in patients with psychosis and Alzheimer's disease (AD). The trial, conducted with 421 ambulatory outpatients found out that in patients with AD and psychosis, olanzapine, quetiapine and risperidone did not improve outcomes and increased the costs of care.


Related Articles

  • Cost of antipsychotic polypharmacy in the treatment of schizophrenia. Zhu, Baojin; Ascher-Svanum, Haya; Faries, Douglas E.; Correll, Christoph U.; Kane, John M. // BMC Psychiatry;2008, Vol. 8, Special section p1 

    Background: This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics -- olanzapine, quetiapine, or risperidone. Methods: Data were drawn from a large, prospective, naturalistic, multi-site, nonrandomized...

  • Dump the drugs. Kirsch, Irving // New Scientist;10/17/2009, Vol. 204 Issue 2730, p26 

    The author calls for the suspension of prescribing antipsychotic drugs to patients with Alzheimer's disease. Examples of such drugs prescribed to patients with Alzheimer's are risperidone and olanzapine. He cites that findings from several studies showed no significant differences between...

  • Movement Disorders in Elderly Users of Risperidone and First Generation Antipsychotic Agents: A Canadian Population-Based Study Vasilyeva, Irina; Biscontri, Robert G.; Enns, Murray W.; Metge, Colleen J.; Alessi-Severini, Silvia // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Despite concerns over the potential for severe adverse events, antipsychotic medications remain the mainstay of treatment of behaviour disorders and psychosis in elderly patients. Second-generation antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine) have generally...

  • Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program. Liu, Gordon G.; Sun, Shawn X.; Christensen, Dale B.; Zhongyun Zhao // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2007, Vol. 47 Issue 1, p77 

    The article discusses the results of a cost analysis of schizophrenia treatment with second-generation antipsychotic medications in the Medicaid program of North Carolina. It showed that olanzapine costs more than risperidone in terms of drug expenditures but is associated with lower use of...

  • Effectiveness and Cost of Risperidone and Olanzapine for Schizophrenia: A Systematic Review. Hargreaves, William A.; Gibson, Joseph P. // CNS Drugs;2005, Vol. 19 Issue 5, p393 

    Risperidone and olanzapine are novel antipsychotic medications that compete as first-line agents in treating patients with schizophrenia. The objective of this paper is to review the available evidence regarding the effectiveness and cost of risperidone versus olanzapine. We reviewed both...

  • An Economic Comparison of Risperidone and Olanzapine Use within an Integrated Managed Mental Health Program. Johnsrud, Michael; Crismon, M. Lynn; Thompson, Ann; Grogg, Amy // Administration & Policy in Mental Health & Mental Health Service;Mar2006, Vol. 33 Issue 2, p237 

    The article presents information on differences in total mental health care costs within an integrated managed mental health pilot project called NorthSTAR with reference to the use of antipsychotic drugs including Risperidone and Olanzapine. This program was initiated to offer mental health...

  • Health care costs for schizophrenia patients started on olanzapine versus risperidone. Russo, Patricia A.; Smith, Mark W.; Namjoshi, Madhav // American Journal of Health-System Pharmacy;3/15/2005, Vol. 62 Issue 6, p610 

    Purpose. The change in direct medical costs for schizophrenia patients who were started on olanzapine or risperidone and who were privately insured was studied. Methods. A retrospective analysis of 1996–1999 data from the databases representing the health care experiences of individuals...

  • Economic Outcomes Associated with Switching Individuals with Schizophrenia Between Risperidone and Olanzapine: Findings from a Large US Claims Database. Zhongyun Zhao; Namjoshi, Madhaw; Barber, Beth L.; Loosbrock, Danielle L.; Tunis, Sandra L.; Zhu, Baojin; Breier, Alan // CNS Drugs;2004, Vol. 18 Issue 3, p157 

    Objectives: To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. Methods: Using a large, integrated medical service and pharmacy...

  • Atypical antipsychotics: are some more atypical than others? Remington, G.; Kapur, S. // Psychopharmacology;2000, Vol. 148 Issue 1, p3 

    Abstract On the heels of clozapine, we now have a number of newer agents (risperidone, olanzapine, quetiapine, sertindole, and ziprasidone). Are they all the same? What are the differences? How do we best understand them? In this article we review current clinical evidence to compare these...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics